Le Congrès canadien sur la santé cardiovasculaire CCSC 2015
Le Congrès canadien sur la santé cardiovasculaire CCSC 2015

CCSC 2017 21 - 24 octobre, 2017 Vancouver, C.-B.

L’horaire Download (.pdf)

8:30

9:00

  • CCC is kicking things off with a much-anticipated lecture from Vancouver’s own Julio Montaner, who revolutionized drug therapy for HIV and played a key role in developing “Treatment as Prevention” which simultaneously decreases progression to AIDS and death as well as HIV transmission. This has all but eliminated AIDS from developed nations. Dr Montaner sees atherosclerosis as the scourge that HIV/AIDS once was, and will present strategies and stories about rethinking our approach to cardiovascular disease.

    Montaner is a Killam Professor of Medicine and Head of the Division of AIDS at the University of British Columbia.  He also holds the endowed Chair in AIDS Research.  He is the Director of the BC Centre for Excellence in HIV/AIDS and the Past-President of the International AIDS Society.  He is the UNAIDS Global Advisor on HIV Therapeutics.

10:00

10:30

11:00

12:00

12:30

13:30

14:00

  • Year in Review Track 1: Decision Making in CAD - “Clinician’s Master’s Class”

    14:00 - 15:00 CC Stagiaire Plenary

    Discussion moderated by David Bewick and Ansar Hassan

    Shaun Goodman: Anti-platelets and anti-coagulants in CAD - Is it really that complicated?
    • Emerging trends in DAPT for post ACS & medically treated patient
      • Post discharge: Duration-shorter is better?
      • 1 year & beyond: Bleeding versus ischemia-which is worse?
    • Is ASA obsolete? The emerging role of DOAC in stable CAD & ACS with sinus rhythm
    Shamir Mehta: PCI & Complex Stable CAD- Controversies and evolving management strategies
    • “Not quite so clear”-PCI vs. CABG in left main disease
    • Medical therapy with versus without revascularization in stable CAD patients with significant “silent” ischemia-case for equipoise?
    • Contemporary role of FFR in selection for revascularization
    • Is revascularization appropriate for CTO?

    Year In Review Track 2: Challenging Traditional Practice in Managing Common Cardiovascular Disorders

    15:00 - 16:00

    Discussion moderated by David Bewick and Brent Mitchell

    David Wood: Evolving controversies and indications for TAVR versus SAVR-time to lower the bar
    • In era of TAVR-who is low risk for SAVR?
    • New guideline recommendations for anticoagulation with recent bioprosthetic valve & TAVR
    • Not in the guidelines...
      • Patients with bicuspid aortic stenosis, prosthetic valve stenosis or severe aortic regurgitation
    Jeff Healey: New perspectives on cardioembolic stroke prevention
    • Atrial fibrillation, PCI and triple therapy redefined: Does ASA add benefit or just risk?
      • Chronic AF & PCI: Single, dual or triple therapy-what is best? (and safest?)
      • New onset atrial fibrillation following PCI with DES
      • NOAC`s in patient with CAD prior to PCI
    • Incidental device detected atrial fibrillation
    • Where are we going with device closure with LAA & PFO?

    Year in Review Track 3: A New Era in the Management of Cardiac Risk Factors and Reducing CV Events

    16:00 - 17:00

    Discussion moderated by David Bewick and John Mancini

    Glen Pearson: “Evolution & Revolution”-The LDL hypothesis is alive and well!
    • PCSK9i- CV morbidity & mortality-they work but are they worth it?
    • What is LDL threshold for initiating PCSK9i?
    • Ultra-low LDL issues & concerns
      • Response needs to be monitored?
      • Discontinue concomitant statin?
      • Neurocognitive, Type 2 diabetes, cataracts and other concerns with ultra-low LDL
    Andrew Pipe: E- cigarettes, marijuana and NRT: Smoke and mirrors?
    • Are e-cigarettes and NRT safe?
    • CV effects of e-cigarettes and concomitant smoking
    • Marijuana, heart failure and stroke
    • Clinician`s advice
  • At the conclusion of this workshop, participants will be able to:

    • Review the current cardiac surgery quality indicators reported annually in the CIHI Cardiac Care Quality Indicators (CCQI) report;
    • Discuss the importance of reporting of both crude and risk-adjusted outcomes, and increase their understanding of the details of the methodology, its assumptions, and limitations; and
    • Understand the features of the interactive spreadsheet used in the CCQI report.
    • James Abel
    • Chantal Couris

    The public release of the CCQI report builds on the long-standing private release of indicator results to cardiac care centres. The purpose of public reporting is to improve transparency and make data more accessible to clinicians and stakeholders; to help support quality improvement efforts. This workshop will assist in informing key internal and external stakeholders of the purpose and benefits of the cardiac care quality indicators. It will serve as a face to face forum to foster and facilitate discussion among targeted stakeholders about the indicators to contribute to knowledge sharing around best practices of care.

    This workshop will:

    • Present the lens through which quality reporting should be presented and interpreted;
    • Present the details of cohort selection, risk factor selection and adjustment, and observed, predicted and risk-adjusted outcomes for the indicators presented;
    • Suggest methods for knowledge translation of the results at hospital and program levels.
  • At the conclusion of this workshop, participants will be able to:

    • Implement strategies to identify patients at high risk for cardiotoxicity from cancer therapy;
    • Recognize and optimize risk factors for cardiotoxicity from cancer therapy; and
    • Implement strategies to foster collaborative care with oncologists and other health care providers.
    • Susan Dent
    • Christopher Johnson
    • Margot Davis
    • Christine Brezden-Masley

    This workshop will demonstrate a range of approaches to solving clinical cardio-oncology problems. Workshop attendees will be able to put into practice a variety of strategies to deliver cardio-oncology services in a way that best fits their local practice. Three cases will be discussed; the first, on the use of Clinical Risk factors, cardiac biomarkers and cardiac imaging to identify patients at a high risk for cardiotoxicity during breast cancer; the second, illustrating the importance of rapid access to cardiologists who can optimize cardiac risk in patients who require therapy for gastro-intestinal cancer; the third case will demonstrate an approach to optimizing cardiovascular health in patients on long-term targeted cancer therapy.

  • New this year, come and learn how to resuscitate! This workshop will provide you with the skills on how to use a defibrillator, establish pace, and run a code through simulated scenarios. Trainees will spend half their time in small group simulations with an expert facilitator, covering basic code algorithms to more complicated scenarios possibly encountered in the CATH lab or CCU. Participants will also have a chance to practice their defibrillation and pacing skills, one-on-one at a skills station.

  • New this year! Interested in cardiac CATH and hemodynamics? Work through basic to advanced hemodynamic problems and learn how to interpret CATH images from leaders in the field! Join us for an exciting case based workshop on cardiac CATH and hemodynamics!

  • Acquiring grant funding can be a tricky business. Learn how to navigate grant applications within industry and academia for the most successful outcome from skilled grant writers! It takes a village to raise funds. Learn how you can be on the winning team.

14:30

15:15

  • At the conclusion of this workshop, participants will be able to:

    • Name the quality indicators for transcatheter aortic valve implantation (TAVI) in Canada;
    • Describe the change in quality of transcatheter aortic valve implantation care delivered in Canada from 2014 to 2017; and
    • List strategies for implantation of the TAVI quality indicators in their local practice.

    This workshop is designed to review: TAVI Quality Indicators; results of the quality report and comparison with the initial report of 2016 ; and new TAVI Quality Benchmarks.

    This workshop will be an interactive panel discussion with short presentations to facilitate audience participation.

15:30

16:00

  • At the conclusion of this workshop, participants will be able to:

    • Discuss the risks and efficacy of anti-arrhythmic drugs in the treatment of atrial fibrillation
    • Discuss patient factors* that alter the risk and efficacy of anti-arrhythmic drugs
    • Discuss the risks and efficacy of pulmonary vein ablation and AV node ablation in the treatment of atrial fibrillation
    • Discuss patient factors* that alter the risk and efficacy of pulmonary vein ablation and AV node ablation in the treatment of atrial fibrillation

    *patient factors to be discussed include duration of atrial fibrillation, LA size and comorbidities such as obesity, hypertension, valvular disease and cardiomyopathy

    In this mini-debate session, experts in the field will try to convince the audience that their position is the correct one. In the first debate, Paul Dorian and Jason Andrade will argue whether medical therapy or ablation should be the initial rhythm control strategy. In the second debate, Tony Tang and Steve Wilton will deliberate on whether patients with long-standing, persistent atrial fibrillation and heart failure are treated with pulmonary vein ablation or AV node ablation. Both pairs of debaters will not only highlight the basic principles, based on literature, to support their argument, but also the practical tips and nuances to aid clinicians making these decisions or referring patients for these procedures.

  • New this year, come and learn how to resuscitate! This workshop will provide you with the skills on how to use a defibrillator, establish pace, and run a code through simulated scenarios. Trainees will spend half their time in small group simulations with an expert facilitator, covering basic code algorithms to more complicated scenarios possibly encountered in the CATH lab or CCU. Participants will also have a chance to practice their defibrillation and pacing skills, one-on-one at a skills station.

  • Back by popular demand! Come and learn how to interpret ECGs in an interactive and dynamic setting with Canada’s top experts. This workshop will introduce trainees to core concepts from beginner to advanced ECG interpretations using a case based approach. An additional focus of this workshop will be ECG interpretation in the setting of devices.

  • Wondering what the job prospects are for a trainee with your skill set? Join us in the trainee lounge as a former section head surveys the landscape for cardiology jobs in Canada. This session will be based on a survey of current department heads around the country.

16:30

  • At the conclusion of this workshop, participants will be able to:

    • Discuss the current landscape of publicly reported PCI quality and outcomes data from cardiac catheterization labs across Canada;
    • Explain the implications of this data being available in the public realm for all stakeholders (patients, administrators, payers, health care providers); and
    • Describe the details of the methodology, the assumptions and limitations of the currently available data and plans for further enhancement.
    • Akshay Bagai
    • Erick Schampaert
    • Warren Cantor

    Calls for public reporting of cardiovascular outcomes have been growing, with transparency being a fundamental component of quality improvement in an emerging era of value based health care. Advocates of public reporting maintain that patients must be able to make informed choices about where to receive their care and that public reporting can drive quality improvement efforts and result in better care. In a seminal initiative, with the endorsement of the Canadian Association of Interventional Cardiology(CAIC), the Canadian Cardiovascular Society (CCS) in partnership with the Canadian Institute for Health Information (CIHI) are slated to publicly-report PCI-related processes as well as outcome measures (30-day mortality and readmission) at the 2017 Canadian Cardiovascular Congress. This workshop will: 

    • Present and discuss the key findings of the publicly reported data;
    • Address the background details, strengths and limitations of the analyses, specifically risk-adjustment;
    • Expand on potential implications of public reporting for all stakeholders; and
    • Discuss future plans to enhance public reporting of PCI data and its potential for cardiovascular care improvements

17:30

Schedule is subject to change without notice